WuXi AppTec's Hong Kong-traded stock jumped 37% as major shareholders JPMorgan Chase, UBS Group, and BlackRock increased their stakes. The company is set to release its half-year earnings on August 3, with high market expectations.
A US congressional advisory panel, the US-China Economic and Security Review Commission, is making its first trip to China in seven years to investigate the national security implications of the two countries' economic and trade relationship. Chairman Randall Schriver stated the trip aims to understand, not reset, the relationship.
The BrioVAD, a compact, magnetically levitated heart pump from China, is being tested in a US clinical trial for advanced heart failure patients. It's the first active implantable medical device from China to gain FDA approval for US trials, aiming to prove its safety and efficacy against the current market leader, HeartMate 3.
Royalty Pharma, the world's largest biopharmaceutical royalty buyer, established its first Asia-Pacific base in Hong Kong. This move aims to capitalize on record Chinese biotech out-licensing deals and offers an alternative financing method amidst US investment restrictions and geopolitical uncertainties.
Goldman Sachs predicts China's rapid aging will boost pharmaceutical and biotech sectors, citing companies like Zai Lab and WuXi XDC Cayman. Conversely, carmakers and tech hardware manufacturers may face challenges due to demographic shifts.
Ukrainian pharmaceutical companies are reportedly exiting the country due to a severe shortage of specialists and labor. Biopharma plans to open an €85 million production facility in Romania by late 2027.
US-China geopolitical tensions may extend to biotechnology as Chinese firms secure record $60B in cross-border deals in Q1 2026, dominating global biotech deal-making. US policymakers express concern over capital fueling China's industry growth.
China ranked third in a new global index measuring competitiveness in AI for biotechnology, healthcare and longevity, as the race to apply AI moves from chatbots and general-purpose models into regulated, data-heavy industries such as drug discovery, diagnostics and preventive medicine. The latest edition of the Global AI Competitiveness Index, released on Monday by Deep Knowledge Group, a consortium focused on deep-tech research, analytics and investment, ranked China behind only the US and UK...
